CDXS Sep 2024 2.500 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 10:36AM EDT. Market open.
| Previous Close | 1.1000 |
| Open | 0.9800 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.50 |
| Expire Date | 2024-09-20 |
| Day's Range | 0.9800 - 1.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
- GuruFocus.com
Codexis Inc (CDXS) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic Advances
Despite a Net Loss, Codexis Demonstrates Strong Revenue Growth and Strategic Milestones
GlobeNewswireCodexis Reports First Quarter 2024 Financial Results
Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer Company is in Final Stages of Enzymatically Synthesizing a Full-Length Oligonucleotide with ECO Synthesis™ Manufacturing Platform and will Provide Update at TIDES USA Meeting REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today an
Simply Wall St.With 74% institutional ownership, Codexis, Inc. (NASDAQ:CDXS) is a favorite amongst the big guns
Key Insights Given the large stake in the stock by institutions, Codexis' stock price might be vulnerable to their...
© 2024 Yahoo. All rights reserved.